CN101341149B - 经色原烷取代的苯并咪唑类和它们作为酸泵抑制剂的用途 - Google Patents

经色原烷取代的苯并咪唑类和它们作为酸泵抑制剂的用途 Download PDF

Info

Publication number
CN101341149B
CN101341149B CN2006800479255A CN200680047925A CN101341149B CN 101341149 B CN101341149 B CN 101341149B CN 2006800479255 A CN2006800479255 A CN 2006800479255A CN 200680047925 A CN200680047925 A CN 200680047925A CN 101341149 B CN101341149 B CN 101341149B
Authority
CN
China
Prior art keywords
reaction
group
alkyl
compound
oxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2006800479255A
Other languages
English (en)
Chinese (zh)
Other versions
CN101341149A (zh
Inventor
花泽毅
小池广记
Original Assignee
Raqualia Pharma Inc
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37912450&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101341149(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Raqualia Pharma Inc, Pfizer Corp SRL filed Critical Raqualia Pharma Inc
Publication of CN101341149A publication Critical patent/CN101341149A/zh
Application granted granted Critical
Publication of CN101341149B publication Critical patent/CN101341149B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/04Drugs for disorders of the respiratory system for throat disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2006800479255A 2005-12-19 2006-12-06 经色原烷取代的苯并咪唑类和它们作为酸泵抑制剂的用途 Active CN101341149B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US75218105P 2005-12-19 2005-12-19
US60/752,181 2005-12-19
US80294406P 2006-05-23 2006-05-23
US60/802,944 2006-05-23
PCT/IB2006/003605 WO2007072146A1 (en) 2005-12-19 2006-12-06 Chromane substituted benzimidazoles and their use as acid pump inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2011101399640A Division CN102321077A (zh) 2005-12-19 2006-12-06 经色原烷取代的苯并咪唑类和它们作为酸泵抑制剂的用途

Publications (2)

Publication Number Publication Date
CN101341149A CN101341149A (zh) 2009-01-07
CN101341149B true CN101341149B (zh) 2011-06-08

Family

ID=37912450

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2011101399640A Pending CN102321077A (zh) 2005-12-19 2006-12-06 经色原烷取代的苯并咪唑类和它们作为酸泵抑制剂的用途
CN2006800479255A Active CN101341149B (zh) 2005-12-19 2006-12-06 经色原烷取代的苯并咪唑类和它们作为酸泵抑制剂的用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN2011101399640A Pending CN102321077A (zh) 2005-12-19 2006-12-06 经色原烷取代的苯并咪唑类和它们作为酸泵抑制剂的用途

Country Status (18)

Country Link
US (1) US7723321B2 (enExample)
EP (1) EP1963311B1 (enExample)
JP (1) JP4481344B2 (enExample)
KR (1) KR101088247B1 (enExample)
CN (2) CN102321077A (enExample)
AR (1) AR058120A1 (enExample)
AT (1) ATE471319T1 (enExample)
BR (2) BRPI0620081B8 (enExample)
CA (1) CA2631880C (enExample)
DE (1) DE602006014996D1 (enExample)
DO (1) DOP2006000285A (enExample)
ES (1) ES2345726T3 (enExample)
GT (1) GT200600514A (enExample)
NL (1) NL2000371C2 (enExample)
PE (1) PE20071182A1 (enExample)
TW (1) TW200732326A (enExample)
UY (1) UY30043A1 (enExample)
WO (1) WO2007072146A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109769392A (zh) * 2016-09-21 2019-05-17 Cj医药健康株式会社 苯并咪唑衍生物的酸加成盐

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009000413A1 (en) * 2007-06-26 2008-12-31 Sanofi-Aventis A regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles
JP5802898B2 (ja) * 2009-07-09 2015-11-04 ラクオリア創薬株式会社 消化管運動異常が関与する疾患を治療するためのアシッドポンプ拮抗剤
KR101472686B1 (ko) 2013-07-09 2014-12-16 씨제이헬스케어 주식회사 벤즈이미다졸 유도체의 제조방법
KR102084185B1 (ko) 2013-08-29 2020-03-04 주식회사 대웅제약 테트라히드로사이클로펜타피롤 유도체 및 이의 제조방법
KR102129842B1 (ko) * 2013-10-02 2020-07-06 주식회사 대웅제약 술포닐인돌 유도체 및 이의 제조방법
RU2693484C1 (ru) 2013-11-22 2019-07-03 СиЭль БАЙОСАЕНСИЗ ЭлЭлСи Антагонисты гастрина для лечения и профилактики остеопороза
CN105440016B (zh) * 2014-08-11 2018-08-31 江苏柯菲平医药股份有限公司 吲哚、氮杂吲哚类衍生物、其制备方法及其在医药上的应用
KR101684053B1 (ko) * 2015-01-20 2016-12-08 씨제이헬스케어 주식회사 벤즈이미다졸 유도체의 신규 결정형 및 이의 제조방법
KR101613245B1 (ko) 2015-04-27 2016-04-18 주식회사 대웅제약 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
SI3305291T1 (sl) * 2015-06-08 2021-08-31 Hk Inno.N Corporation Uporabe benzimidazolnega derivata za nočno izločanje kisline
KR101769204B1 (ko) * 2015-08-04 2017-08-17 씨제이헬스케어 주식회사 크로마놀 유도체의 신규한 제조방법
KR101777971B1 (ko) 2016-07-05 2017-09-12 제일약품주식회사 이미다조[1,2-a]피리딘 유도체, 이의 제조방법 및 이의 용도
KR101829685B1 (ko) * 2016-07-28 2018-02-19 씨제이헬스케어 주식회사 안정성 및 용해도가 개선된 주사용 조성물
KR101829705B1 (ko) * 2016-09-21 2018-02-19 씨제이헬스케어 주식회사 안정성이 향상된 주사용 조성물
US11142591B2 (en) * 2016-12-20 2021-10-12 Exxonmobil Chemical Patents Inc. Polymerization process
KR101960357B1 (ko) 2016-12-26 2019-03-20 씨제이헬스케어 주식회사 벤즈이미다졸 유도체를 포함하는 신규한 제제
KR102233456B1 (ko) * 2017-05-31 2021-03-29 주식회사 대웅제약 4-메톡시피롤 유도체의 중간체 제조 방법
KR102262743B1 (ko) * 2017-07-07 2021-06-09 에이치케이이노엔 주식회사 주사용 조성물
KR20190057569A (ko) 2017-11-20 2019-05-29 제일약품주식회사 7-아미노-1h-인돌-5-카르복사미드 유도체 및 이의 용도
TWI676477B (zh) * 2017-12-05 2019-11-11 南韓商Cj醫藥健康股份有限公司 苯并咪唑衍生物用於夜間酸突破的用途
JOP20190198A1 (ar) * 2018-08-28 2020-02-28 Hk Inno N Corp تركيبة صيدلانية تشتمل على عامل مضاد للصفيحات ومثبط إفراز حمض معدي
JOP20190201A1 (ar) * 2018-08-29 2020-02-29 Hk Inno N Corp تركيبة لاستئصال الملوية البوابية
CN109320485B (zh) * 2018-12-02 2021-06-18 江苏慧聚药业有限公司 合成特戈拉赞手性醇的方法
JP2022520276A (ja) 2019-02-18 2022-03-29 エイチケー イノ.エヌ コーポレーション ベンズイミダゾール誘導体化合物を含む医薬組成物
CN112851646B (zh) * 2019-11-12 2023-06-13 中国医学科学院药物研究所 特戈拉赞的制备方法
UY39094A (es) * 2020-02-27 2021-07-30 Hk Inno N Corp Composición farmacéutica que comprende compuesto derivado de bencimidazol
CN111303131B (zh) * 2020-03-19 2021-06-04 江苏慧聚药业有限公司 特戈拉赞(Tegoprazan)类似物及其合成方法
AU2021256161A1 (en) * 2020-04-13 2022-12-15 Hk Inno.N Corporation Pharmaceutical composition comprising benzimidazole derivative compound
CN114249694B (zh) * 2020-09-22 2025-06-17 浙江四维医药科技有限公司 一种特格拉赞中间体的制备方法
CN116507318A (zh) * 2020-10-23 2023-07-28 怡诺安有限公司 包含苯并咪唑衍生物化合物的口服崩解片剂及其制备方法
CN112358450A (zh) * 2020-11-19 2021-02-12 南京艾康生物科技有限公司 一种4-(苄氧基)-2-甲基-1H-苯并[d]咪唑-6-羧酸的合成方法
KR20220141700A (ko) 2021-04-13 2022-10-20 에이치케이이노엔 주식회사 벤즈이미다졸 유도체 화합물을 포함하는 약학적 조성물
CN113527272B (zh) * 2021-08-06 2023-07-21 西安淳甄新材料有限公司 一种特戈拉赞的合成方法
CN118355013A (zh) * 2021-12-08 2024-07-16 制药基因科学株式会社 苯并咪唑衍生物化合物及其用途
KR102708701B1 (ko) * 2021-12-27 2024-09-24 에이치케이이노엔 주식회사 벤즈이미다졸 유도체의 제조방법
CN114805317A (zh) * 2022-05-20 2022-07-29 江苏威奇达药业有限公司 一种特戈拉赞的制备方法
US12060148B2 (en) 2022-08-16 2024-08-13 Honeywell International Inc. Ground resonance detection and warning system and method
KR20240028127A (ko) 2022-08-24 2024-03-05 위더스제약주식회사 테고프라잔 고체분산체 조성물
WO2024045255A1 (zh) * 2022-08-30 2024-03-07 上海皓元医药股份有限公司 一种特戈拉赞晶型b及其制备方法
WO2024087155A1 (zh) * 2022-10-28 2024-05-02 深圳市华先医药科技有限公司 一种合成4-羟基-n,n,2-三甲基苯并咪唑-6-甲酰胺的方法
WO2024087156A1 (zh) * 2022-10-28 2024-05-02 深圳市华先医药科技有限公司 4-羟基-n,n,2-三甲基苯并咪唑-6-甲酰胺的可放大生产方法
CN116253685B (zh) * 2022-12-30 2024-12-10 成都安满生物医药科技有限公司 一种特戈拉赞中间体的制备方法
KR20240109898A (ko) 2023-01-05 2024-07-12 위더스제약주식회사 무정형 테고프라잔 고체분산체
KR20240118377A (ko) 2023-01-27 2024-08-05 스마트바이오팜 주식회사 테고프라잔 중간체를 제조하는 방법 및 이에 사용되는 신규 중간체
KR102638900B1 (ko) 2023-01-27 2024-02-21 스마트바이오팜 주식회사 테고프라잔 중간체를 제조하는 방법 및 이에 사용되는 신규 중간체
WO2024171128A1 (en) * 2023-02-18 2024-08-22 Lee Pharma Limited Stable amorphous form of potassium-competitive acid blocker and process for the preparation thereof
KR20240131641A (ko) 2023-02-24 2024-09-02 엠에프씨 주식회사 신규 테고프라잔의 염 결정형 및 이의 용매화물 결정형, 및 이들의 제조방법
KR102715562B1 (ko) * 2023-03-16 2024-10-11 (주) 에프엔지리서치 테고프라잔의 신규 염 및 이의 제조 방법
CN118724858B (zh) * 2023-03-31 2025-09-19 上海医药工业研究院有限公司 一种(r)-苯并吡喃-4-醇类化合物的制备方法
KR20250164238A (ko) * 2023-04-07 2025-11-24 제이더블유중외제약 주식회사 벤즈이미다졸 유도체의 염
CN116621821A (zh) * 2023-05-29 2023-08-22 宙晟智维生命科学(上海)有限公司 一种无定形的苯并咪唑基化合物及固体分散体
KR20240171624A (ko) 2023-05-31 2024-12-09 권대길 치환된 벤즈이미다졸의 결정형 및 이의 제조방법
CN116715660A (zh) * 2023-06-14 2023-09-08 上海柏狮生物科技有限公司 一种特格拉赞的无定型物及其制备方法
CN117024417A (zh) * 2023-06-27 2023-11-10 上海柏狮生物科技有限公司 一种特格拉赞的制备方法
CN116789654A (zh) * 2023-07-10 2023-09-22 杭州小蓓医药科技有限公司 一种特戈拉赞的制备方法
WO2025037242A1 (en) * 2023-08-14 2025-02-20 Ami Lifesciences Private Limited Solid forms of tegoprazan and process thereof
KR102689851B1 (ko) 2023-09-26 2024-07-30 스마트바이오팜 주식회사 테고프라잔 중간체를 제조하는 방법 및 이에 사용되는 신규 중간체
TW202535866A (zh) * 2023-11-01 2025-09-16 日商拉夸里亞創藥股份有限公司 苯并咪唑化合物的製造製程
KR20250066641A (ko) 2023-11-07 2025-05-14 엠에프씨 주식회사 테고프라잔 말리에이트염 1수화물 결정형 및 이의 제조방법
CN117903097A (zh) * 2024-01-04 2024-04-19 浙江永太科技股份有限公司 一种特戈拉赞关键中间体母液料的回收方法
KR20250118583A (ko) 2024-01-30 2025-08-06 진양제약주식회사 테고프라잔을 포함하는 제약 조성물
KR102825970B1 (ko) 2024-02-16 2025-06-26 스마트바이오팜 주식회사 테고프라잔 중간체를 제조하는 방법 및 이에 사용되는 신규 중간체

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004054984A1 (en) * 2002-12-13 2004-07-01 Altana Pharma Ag 4-substituted benzimidazoles and their use as inhibitors of gastric secretion
WO2005111000A1 (en) * 2004-05-18 2005-11-24 Altana Pharma Ag 7-substituted benzimidazoles and their use as inhibitors of gastric acid secretion

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8604566D0 (sv) * 1986-10-27 1986-10-27 Haessle Ab Novel compunds
US5444775A (en) 1993-11-09 1995-08-22 Tobish; John J. Telephone key selection aid
SE9602286D0 (sv) * 1996-06-10 1996-06-10 Astra Ab New compounds
GB9914022D0 (en) 1999-06-17 1999-08-18 Zeneca Ltd Chemical compounds
EP1893197B1 (en) * 2005-06-14 2009-09-09 RaQualia Pharma Inc Chromane substituted benzimidazole derivatives as acid pump antagonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004054984A1 (en) * 2002-12-13 2004-07-01 Altana Pharma Ag 4-substituted benzimidazoles and their use as inhibitors of gastric secretion
WO2005111000A1 (en) * 2004-05-18 2005-11-24 Altana Pharma Ag 7-substituted benzimidazoles and their use as inhibitors of gastric acid secretion

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109769392A (zh) * 2016-09-21 2019-05-17 Cj医药健康株式会社 苯并咪唑衍生物的酸加成盐
CN109769392B (zh) * 2016-09-21 2022-06-24 怡诺安有限公司 苯并咪唑衍生物的酸加成盐
US11535610B2 (en) 2016-09-21 2022-12-27 Hk Inno.N Corporation Acid addition salts of benzimidazole derivative

Also Published As

Publication number Publication date
KR101088247B1 (ko) 2011-11-30
WO2007072146A1 (en) 2007-06-28
US20070142448A1 (en) 2007-06-21
US7723321B2 (en) 2010-05-25
ES2345726T3 (es) 2010-09-30
BRPI0620081B1 (pt) 2020-10-20
DOP2006000285A (es) 2007-07-31
UY30043A1 (es) 2007-07-31
NL2000371C2 (nl) 2007-09-06
TW200732326A (en) 2007-09-01
PE20071182A1 (es) 2008-02-07
BRPI0620081B8 (pt) 2021-05-25
JP4481344B2 (ja) 2010-06-16
NL2000371A1 (nl) 2007-06-20
AR058120A1 (es) 2008-01-23
BRPI0620081A2 (pt) 2011-11-01
CN101341149A (zh) 2009-01-07
CA2631880A1 (en) 2007-06-28
DE602006014996D1 (de) 2010-07-29
CA2631880C (en) 2011-03-29
CN102321077A (zh) 2012-01-18
ATE471319T1 (de) 2010-07-15
JP2009520017A (ja) 2009-05-21
EP1963311B1 (en) 2010-06-16
EP1963311A1 (en) 2008-09-03
HK1125368A1 (en) 2009-08-07
BR122020004679B1 (pt) 2021-09-21
GT200600514A (es) 2007-07-17
KR20080080195A (ko) 2008-09-02

Similar Documents

Publication Publication Date Title
CN101341149B (zh) 经色原烷取代的苯并咪唑类和它们作为酸泵抑制剂的用途
TWI469979B (zh) 脂肪酸醯胺水解酶(faah)抑制劑、以及其藥學組成物與用途
CN101193869B (zh) 糖皮质激素模拟物、其制备方法、药物组合物及其用途
AU2005244736B2 (en) Raf modulators and methods of use
AU2009247262B2 (en) Amide compound
CN101918376B (zh) 用作硬脂酰-辅酶a去饱和酶抑制剂的1,2,3-三唑衍生物
JP5140080B2 (ja) 選択的アシッドポンプ阻害剤としてのベンゾイミダゾール誘導体
CN101547909A (zh) 糖皮质激素模拟物、其制备方法、药物组合物及其用途
CN110546140A (zh) 选择性hdac6抑制剂
EP3027602A1 (fr) Nouveaux derives d'indole et de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2984971A1 (en) Benzimidazole derivates useful as inhibitors of mammalian histone deacetylase activity
CN107849049A (zh) 脲衍生物或其药用盐
JP2008543824A (ja) アシッドポンプアンタゴニストとしてのクロマン置換ベンゾイミダゾール誘導体
CN101677548A (zh) 硬骨鱼紧张肽ⅱ受体拮抗剂
JP2009530262A (ja) クロマン誘導体
CN106496132B (zh) N-(4-取代苯基)-2-取代乙酰胺类化合物及其作为sirt2蛋白抑制剂的用途
HK1163065A (en) Chromane substituted benzimidazoles and their use as acid pump inhibitors
HK1125368B (en) Chromane substituted benzimidazoles and their use as acid pump inhibitors
WO2007072142A2 (en) Benzimidazole-5-carboxamide derivatives
CN101528750B (zh) 作为选择性酸泵抑制剂的苯并咪唑衍生物
WO2007031860A1 (en) Indane substituted benzimidazoles and their use as acid pump inhibitors
MX2008007030A (en) Chromane substituted benzimidazoles and their use as acid pump inhibitors
HK1132993A (en) Benzimidazole derivatives and selective acid pump inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20090206

Address after: Aichi

Applicant after: Raqualia Pharma Inc.

Address before: American New York

Applicant before: Smithkline Beecham PLC

ASS Succession or assignment of patent right

Owner name: GLIARELLA MEDICINE CO., LTD.

Free format text: FORMER OWNER: AGOURON PHARMA

Effective date: 20090206

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1125368

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
EE01 Entry into force of recordation of patent licensing contract

Assignee: CJ Corp.

Assignor: Raqualia Pharma Inc.

Contract record no.: 2011990000915

Denomination of invention: Chromane substituted benzimidazoles and their use as acid pump inhibitors

Granted publication date: 20110608

License type: Exclusive License

Open date: 20090107

Record date: 20110921

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1125368

Country of ref document: HK

EC01 Cancellation of recordation of patent licensing contract

Assignee: CJ Corp.

Assignor: Raqualia Pharma Inc.

Contract record no.: 2011990000915

Date of cancellation: 20150410

LICC Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model
EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20090107

Assignee: Shandong Luo Xin Pharmaceutical Group Plc

Assignor: CJ CHEILJEDANG CORPORATION

Contract record no.: 2016990000057

Denomination of invention: Chromane substituted benzimidazoles and their use as acid pump inhibitors

Granted publication date: 20110608

License type: Exclusive License

Record date: 20160302

LICC Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model
EM01 Change of recordation of patent licensing contract
EM01 Change of recordation of patent licensing contract

Change date: 20220221

Contract record no.: 2016990000057

Assignor after: Inoon Ltd.

Assignor before: CJ HEALTHCARE Corp.